Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Influences of Angiotensin-neprilysin Inhibition With Sacubitril/Valsartan (ENTRESTO) on Centrally Generated Sympathetic Activity in Heart Failure Patients

Trial Profile

Influences of Angiotensin-neprilysin Inhibition With Sacubitril/Valsartan (ENTRESTO) on Centrally Generated Sympathetic Activity in Heart Failure Patients

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 16 Oct 2018

At a glance

  • Drugs Sacubitril/valsartan (Primary) ; Valsartan
  • Indications Heart failure
  • Focus Pharmacodynamics
  • Acronyms ARNI-Sy
  • Most Recent Events

    • 05 Oct 2018 Status changed to withdrawn prior to enrolment, the reason provided is Difficulties in recruiting patients.
    • 05 Oct 2018 Planned End Date changed from 31 Dec 2020 to 6 Sep 2018.
    • 05 Oct 2018 Planned primary completion date changed from 31 Mar 2020 to 6 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top